- Home
- NRXP vs ANL Comparison
NRXP vs ANL Comparison
Compare NRXP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXP | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NRXP | ANL |
|---|---|---|
| Price | $2.08 | $1.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 461.9K | 28.5K |
| Earning Date | 11-17-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.88 |
| 52 Week High | $6.01 | $2.99 |
Technical Indicators
Market Signals| Indicator | NRXP | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 51.04 |
| Support Level | $2.22 | $0.88 |
| Resistance Level | $2.39 | $1.59 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 4.26 | 70.48 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.